Cargando…

Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden

OBJECTIVES: Stat3 is persistently activated in ovarian cancer cells, with a crucial role in tumour onset and progression. In this study, we examined the anti‐tumour effect of a small‐molecule inhibitor napabucasin (BBI608) on epithelial ovarian cancer (EOC) in vitro and in vivo, and investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hongyi, Qian, Yanping, Wang, Xi, Pi, Ruyu, Zhao, Xia, Wei, Xiawei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985655/ https://www.ncbi.nlm.nih.gov/pubmed/31778258 http://dx.doi.org/10.1111/cpr.12719

Ejemplares similares

Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer
por: Zheng, Heng, et al.
Publicado: (2019)

Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden
por: Abubaker, Khalid, et al.
Publicado: (2014)

The effects of dexamethasone on the proliferation and apoptosis of human ovarian cancer cells induced by paclitaxel
por: Hou, Wenjing, et al.
Publicado: (2014)

MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer
por: Silasi, Dan-Arin, et al.
Publicado: (2007)

Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer
por: Park, Sun-Ae, et al.
Publicado: (2022)

Retraction Note: The effects of dexamethasone on the proliferation and apoptosis of human ovarian cancer cells induced by paclitaxel
por: Hou, Wenjing, et al.
Publicado: (2015)

Metformin Reduces NGF-Induced Tumour Promoter Effects in Epithelial Ovarian Cancer Cells
por: Garrido, Maritza P., et al.
Publicado: (2020)

Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
por: Wang, Huan, et al.
Publicado: (2022)

CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro
por: ZHU, ZHUANGYAN, et al.
Publicado: (2015)

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.
por: Siddiqui, N., et al.
Publicado: (1997)

Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells
por: Scharer, Christopher D, et al.
Publicado: (2008)

Piperlongumine Induces Apoptosis and Synergizes with Cisplatin or Paclitaxel in Human Ovarian Cancer Cells
por: Gong, Li-Hua, et al.
Publicado: (2014)

Inhibition of paclitaxel resistance and apoptosis induction by cucurbitacin B in ovarian carcinoma cells
por: Qu, Yingchun, et al.
Publicado: (2017)

Treatment with β-elemene combined with paclitaxel inhibits growth, migration, and invasion and induces apoptosis of ovarian cancer cells by activation of STAT-NF-κB pathway
por: Xiaomeng, Fu, et al.
Publicado: (2020)

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
por: Mullany, Sally, et al.
Publicado: (2020)

Knockout of vasohibin‐2 reduces tubulin carboxypeptidase activity and increases paclitaxel sensitivity in ovarian cancer
por: Koyanagi, Takahiro, et al.
Publicado: (2021)

Ovarian tumour xenografts in the study of the biology of human epithelial ovarian cancer.
por: Friedlander, M. L., et al.
Publicado: (1985)

Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations
por: Jean, Stephanie, et al.
Publicado: (2016)

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
por: Gao, Bo, et al.
Publicado: (2018)

NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
por: Saldanha, Elroy, et al.
Publicado: (2022)

Highly expressed STAT1 contributes to the suppression of stemness properties in human paclitaxel-resistant ovarian cancer cells
por: Wang, Fanchen, et al.
Publicado: (2020)

Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
por: Osman, Mohammed A., et al.
Publicado: (2016)

Role of tumour markers in monitoring epithelial ovarian cancer
por: Meyer, T, et al.
Publicado: (2000)

Phosphorylation of STAT3 at Tyr705 regulates MMP-9 production in epithelial ovarian cancer
por: Jia, Zan-Hui, et al.
Publicado: (2017)

Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity
por: Wu, Chin-Jui, et al.
Publicado: (2019)

Characterization of tumour microenvironment reprogramming reveals invasion in epithelial ovarian carcinoma
por: Zhang, Yuanfu, et al.
Publicado: (2023)

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
por: Oliva, P, et al.
Publicado: (2012)

Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma
por: Li, Xiao, et al.
Publicado: (2015)

Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer
por: He, Jing, et al.
Publicado: (2019)

Dicer affects cisplatin-mediated apoptosis in epithelial ovarian cancer cells
por: Wang, Xi, et al.
Publicado: (2018)

Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer
por: Ingemarsdotter, C K, et al.
Publicado: (2010)

Human lymphatic endothelial cells contribute to epithelial ovarian carcinoma metastasis by promoting lymphangiogenesis and tumour cell invasion
por: XIE, YIHONG, et al.
Publicado: (2016)

Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy — non-mitotic mechanisms of paclitaxel
por: Smith, Elizabeth R., et al.
Publicado: (2022)

Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review
por: Li, Ying, et al.
Publicado: (2014)

CHFR and Paclitaxel Sensitivity of Ovarian Cancer
por: Wahner Hendrickson, Andrea E., et al.
Publicado: (2021)

Inhibition of Notch Signaling in Combination with Paclitaxel Reduces Platinum-Resistant Ovarian Tumor Growth
por: Groeneweg, Jolijn W., et al.
Publicado: (2014)

Identification of proteins associated with paclitaxel resistance of epithelial ovarian cancer using iTRAQ-based proteomics
por: Wang, Yuanjing, et al.
Publicado: (2018)

Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
por: Broekman, K. Esther, et al.
Publicado: (2020)

STAT4 targets KISS1 to promote the apoptosis of ovarian granulosa cells
por: Jiang, Yao, et al.
Publicado: (2020)

Nuclear expression of Snail1 in borderline and malignant epithelial ovarian tumours is associated with tumour progression
por: Tuhkanen, Hanna, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_u19otv3l5cdto03gqejivfooet